NCT01203319View on ClinicalTrials.gov

The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,091

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

December 31, 2010

Study Completion Date

March 31, 2011

Conditions
Hepatitis b
Interventions
BIOLOGICAL

60mcg/1.0ml recombinant hepatitis B vaccine

to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60

BIOLOGICAL

30mcg/1.0ml recombinant hepatitis B vaccine

to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.

BIOLOGICAL

10mcg/1.0ml recombinant hepatitis B vaccine

to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60

All Listed Sponsors
collaborator

Shenzhen Kangtai Biological Products Co., LTD

INDUSTRY

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT01203319 - The Immunogenicity and Safety of 60mcg/30mcg Recombinant Hepatitis B Vaccines in People Who Failed to Respond to Routine Administration of Hepatitis B Vaccines | Biotech Hunter | Biotech Hunter